Campbell Capital Management Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 127,280 shares of the biopharmaceutical company’s stock after selling 2,950 shares during the period. Pfizer comprises 2.3% of Campbell Capital Management Inc.’s investment portfolio, making the stock its 17th biggest position. Campbell Capital Management Inc.’s holdings in Pfizer were worth $4,732,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in PFE. NuWave Investment Management LLC increased its stake in shares of Pfizer by 439.7% during the third quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,196 shares in the last quarter. Dimension Capital Management LLC acquired a new position in Pfizer during the third quarter worth $58,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in Pfizer during the third quarter worth $59,000. Demars Financial Group LLC acquired a new position in Pfizer during the second quarter worth $75,000. Finally, RMR Wealth Builders purchased a new position in Pfizer during the second quarter worth $91,000. 69.08% of the stock is owned by institutional investors and hedge funds.

Shares of Pfizer stock opened at $36.86 on Thursday. The stock has a market cap of $204.88 billion, a PE ratio of 14.63, a price-to-earnings-growth ratio of 3.10 and a beta of 0.66. The business has a fifty day simple moving average of $38.25 and a 200-day simple moving average of $37.19. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $43.08.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.01. The business had revenue of $12.13 billion during the quarter, compared to analysts’ expectations of $12.30 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. Pfizer’s revenue was down 4.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Analysts expect that Pfizer Inc. will post 2.84 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Stockholders of record on Friday, January 29th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 4.23%. The ex-dividend date is Thursday, January 28th. This is a boost from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s dividend payout ratio (DPR) is 51.53%.

In other news, major shareholder Pfizer Inc acquired 1,200,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 27th. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $12,000,000.00. Following the completion of the acquisition, the insider now owns 27,349,211 shares in the company, valued at $273,492,110. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.08% of the company’s stock.

A number of brokerages have recently commented on PFE. Berenberg Bank began coverage on Pfizer in a research report on Tuesday, September 29th. They issued a “hold” rating and a $38.00 price objective for the company. The Goldman Sachs Group set a $40.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Friday, January 8th. BidaskClub cut Pfizer from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 31st. SVB Leerink upped their price objective on Pfizer from $42.00 to $43.00 and gave the company a “market perform” rating in a research note on Wednesday, October 28th. Finally, Mizuho increased their target price on Pfizer from $43.00 to $44.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $39.87.

About Pfizer

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Further Reading: What is a Fiduciary?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.